Palisade Bio (PALI) Liabilities and Shareholders Equity (2010 - 2026)

Palisade Bio (PALI) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $133.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 1527.78% year-over-year to $133.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.3 million (up 581.49% YoY) and the FY2025 annual result came in at $134.3 million, up 1134.78% from the prior year.
• Liabilities and Shareholders Equity retreated to $133.3 million in Q1 2026 per PALI's latest filing, from $134.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $134.3 million in Q4 2025 and bottomed at $6.7 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $12.9 million (2024), against an average of $26.4 million.
• The widest annual swing landed in 2025, when Liabilities and Shareholders Equity plunged 48.2%; it then jumped 1527.78% in 2026.
• Tracing PALI's Liabilities and Shareholders Equity over 5 years: stood at $15.8 million in 2022, then fell by 10.85% to $14.1 million in 2023, then declined by 22.57% to $10.9 million in 2024, then jumped by 1134.78% to $134.3 million in 2025, then fell by 0.77% to $133.3 million in 2026.
• Per Business Quant, the three latest PALI Liabilities and Shareholders Equity figures stand at $133.3 million (Q1 2026), $134.3 million (Q4 2025), and $7.0 million (Q3 2025).

Peer Comparison